A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
Completed · Phase 1
Conditions studied: Hepatic Insufficiency
In brief
The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.
Key facts
- Study ID
- NCT06858696
- Run by
- X4 Pharmaceuticals
- People needed
- 39
- Starts
- 2025-02-28
- Expected to finish
- 2026-01-12
- Last updated by the study team
- 2026-07-15
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Catalina Research Institute, LLC — Montclair, California, United States
- Catalina Research Institute, LLC — Rialto, California, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- Texas Liver Institute/Alamo Medical Research — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.